Fujitsu and ACRES have linked up to address challenges facing the development of medicines and health-related research endeavors.
Fujitsu and ACRES have linked up to address challenges facing the development of medicines and health-related research endeavors.
Fujitsu, the Japanese information and communication technology company, and the Alliance for Clinical Research Excellence and Safety (ACRES) have linked up to address challenges facing the development of medicines and health-related research endeavors.
Fujitsu and ACRES are establishing a technical working party, the ACRES-Fujitsu Technology Innovation Group, to explore closer alignment of electronic medical records (EMRs) and clinical research information systems, which they regard as an essential step toward enabling innovative systems capabilities, including remote risk-based monitoring, online electronic auditing, and real-time pharmacovigilance safety monitoring.
The partnership is part of a larger collaborative effort, the ACRES Technology Consortium, to work out how information and communications technology can be more innovatively and effectively applied within the healthcare and health-research domains in Japan and across the ACRES Global Technology Network, in support of ACRES global system for clinical research.
“We are honored to have Fujitsu, Ltd. as our newest ally and strategic partner,” said Al Pacino, ACRES Vice-President for Collaborative Network Development. “Fujitsu’s expertise brings extraordinary resources to ACRES global technology initiatives—this is a major milestone. Successful integration of electronic health records and clinical trials information greatly furthers ACRES goal to get safe, effective medicines to the people who need them as efficiently as possible.”
Head of Fujitsu’s Next Generation Healthcare Innovation Center, Hirofumi Gouda, notes that “Fujitsu has high expectations that ACRES efforts and the Global Network System will not only greatly improve Quality Cost Delivery in the related areas in clinical trials and clinical research, but also become a very important collaborative platform for helping creating a new knowledge base, including an evolving collaboration with stakeholders in healthcare and life science worldwide.”
ACRES President and CEO, Dr. Greg Koski, added, “Emerging from the efforts of Dr. Kyoko Imamura and our colleagues at ACRES Japan, including its President, Dr Fumimaro Takaku, our partnership with Fujitsu is a landmark event. The decision of one of the world’s leading technology companies to join the ACRES Alliance attests to the power of systems thinking and multi-sector collaboration. The world of medicines development is undergoing transformation, and Fujitsu is helping ACRES Allies envision and build the future.”
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.